Verce,
I think you mean the loss blew out by over 100%. Costs (expenses) went from $5.8M to $7.6M but included a non cash writedown of $2M. Without that, costs would have improved slightly from last year. Revenue, on the other hand went from $3.8M down to $2.9M due in part to $.6 R&D grant not being received in the reporting period. Sales revenue fell from $3M to $2.8M which aint great (but see @edshann 's post on that). Not trying to sugar coat anything here but they did re-iterate their guidance on $7.5M sales pipeline for the coming half. Still a super risky stock (IMO) but I will hold for the next haft yearly and reassess then.
- Forums
- ASX - By Stock
- VIV
- Ann: Appendix 4D Half Year Report
Ann: Appendix 4D Half Year Report, page-7
Featured News
Add VIV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
UNT
UNITH LTD
Idan Schmorak, CEO
Idan Schmorak
CEO
Previous Video
Next Video
SPONSORED BY The Market Online